Grant Overview

A global consortium studying cognitive decline and ADRD risk after COVID-19

ISAVRAD brings together longitudinal clinical, neuroimaging, biomarker, and genomic research across diverse populations to study how SARS-CoV-2 exposure may intersect with aging and dementia risk.

Scientific opportunity

Program overview

The science in this program takes advantage of the unique research opportunity created by the coronavirus pandemic to study how viral exposure and genomic variation may influence cognitive decline and Alzheimer’s disease and related dementias in older adults.

The program includes newly recruited cohorts in Texas, New York, Washington State, and Jujuy, Argentina, with repeated assessments spanning clinical, cognitive, imaging, and blood- and CSF-based biomarker domains.

Consortium partners

Networked institutions

  • National Institutes of Health
  • National Institute on Aging
  • Alzheimer’s Association
  • Universidad de Buenos Aires
  • FULTRA
  • Gobierno de Jujuy
  • Universidad Católica Argentina
  • Albert Einstein College of Medicine
  • UT Health San Antonio
  • UT Health in Laredo
  • City of Laredo
  • University of Washington in Seattle
  • Washington University in St. Louis
  • University of Miami, NIAGADS
  • University of Pennsylvania, NIAGADS and GCAD
  • University of Indiana, NCRAD
  • UT Rio Grande Valley
  • University of California, Irvine

Research aims

Aim 1

Assess risk of cognitive decline

Determine whether SARS-CoV-2-related neuropsychiatric and cognitive sequelae increase risk of ADRD, earlier onset, or faster progression.

Aim 2

Identify risk and resilience factors

Study environmental, genetic, clinical, and imaging predictors that may shape vulnerability or protection.

Aim 3

Track longitudinal course

Describe trajectories of decline and interaction effects across diverse ancestral and admixed populations.

Aim 4

Study gene by environment effects

Examine interactions predictive of decline and progression using whole genome sequencing across underrepresented groups.

Aim 5

Identify neural signatures

Describe neuroimaging markers linked to anosmia, cognitive impairment, and risk of progression.

Aim 6

Support prevention strategy development

Deepen understanding of shared pathophysiology and inform future prevention approaches for both COVID-related sequelae and ADRD.

Sites

Data collected across diverse regions

The study spans urban and rural populations and focuses on communities often underrepresented in genetic and aging datasets. Self-report is documented, but quantitative ancestry indices derived from genetic data support analytic interpretation.

Integration

Collaborative resources and expertise

Resources and study expertise are coordinated across multiple sites and cores and integrated with major Alzheimer’s research infrastructure, helping support strong knowledge sharing and future reuse of resulting data.